Annexe O

Bibliography

February 2007

OFT885o
© Crown copyright 2007

This publication (excluding the OFT logo) may be reproduced free of charge in any format or medium provided that it is reproduced accurately and not used in a misleading context. The material must be acknowledged as crown copyright and the title of the publication specified.
Bibliography

3T study (2003), Clinical Therapy, 25.

Abacus Study (2005), ‘NICE guidance, implementation tracking, data sources, methodology and results’


ABPI proposal, 27 May 2004

Accountability and Management, February, 13:1


Adria-Wien Pipeline GmbH, C-379/98, C-143/99


Allen and Harkins (2005), Lancet, (365), p1768

Article 100 of Law 25/1990 (Ley del Medicamento)


Bloom, N. and Van Reenen, J (1998), ‘Regulating Drug Prices: Where do We Go from Here?’, Fiscal Studies, 19.3


Carltona Ltd. v Commissioners of Works [1943] 2All ER 540.


CHMP Guideline on similar biological products (CHMP/437/04)

CHMP Note for Guidance on the Investigation of bioavailability and bioequivalence, (CPMP/EWP/QWP/1401/98)


Colonna (2005), ‘A randomized, double-blind 24 week study of escitalopram (10mg/day) versus citalopram (20mg/day) in primary care patients with major depressive disorder’, Current Medical Research and Opinion, 21.

Commercial Solvents Cases C-6/73

Commission Decision 2001/791/EC

Commission Decision 2006/857/EC – CFI case T-321/05 challenge


Commission v Austria, ECJ C-424/99

Commission v Belgium (Case 249/88, [1991] ECR I 1275)


Commission v Finland Case C-229/00.

Commission v Italy (Case 56/87, [1988] ECR 2919)

Commission v Italy, Case 56/87, [1988] ECR 2919

Competition Act 1998


Danzon P and Furukawa, M (2003), ‘Prices and availability of pharmaceuticals: Evidence from nine countries’, Health Affairs Web Exclusive, October;


Department of Health 'NHS organisations forecast surplus and deficits 2005-06: Month 6'


Department of Health/ABPI (2002), 'PPRS: The Study into the Extent of Competition in the Supply of Branded Medicines to the NHS'.

Department of Health(2000), National Service Framework on coronary heart disease


Directive 2001/83/EEC

Drug Tariff for England and Wales, Part XVIII C.


EC Treaty, Articles: 28, 30, 81, 82, 87, 234

Eden, L (1998), 'Taxing multinationals; transfer pricing and corporate income taxation in North America’, Toronto, University of Toronto Press.


European Federation of Pharmaceutical Industries Association, Annual report 2004

Federation of Icelandic Trade v Iceland, EFTA E-2/98


Fraser Group/ Tristat Resources, (2002), Drug expense coverage in the Canadian population: protection from severe drug expenses

Glaxosmithkline SA v Belgium, ECJ C-296/03

GlaxoSmithKline Services Unlimited v Commission of the European Com, Case CJE/06/79 - Judgment of the Court of First Instance in Case T-168/01

GlaxoSmithKline Services Unlimited v Commission, CFI Case T-168/01

Government of Wales Act 1998


Health Act 1999, Sections 33-38.

Health Select Committee Report 2004-05 on the influence of the pharmaceutical industry in www.parliament.uk

Health Service Medicines (Consent to Voluntary Scheme) Regulations 1999.

Health Service Medicines (Control of Prices of Branded Medicines) Regulations 2000

Health Service Medicines (Control of Prices of Specified Generic Medicines) Regulations 2000.

Health Service Medicines (Information on the Prices of Specified Generic Medicines) Regulations 2001.

Health Service Medicines (Price Control Appeals) Regulations 2000.


HM Revenue and Customs,(2005), ‘R&D tax Credits Final Report December 2005’


HPS study (2002), Lancet, 360.


IMS ‘Global Pharmaceutical Perspectives 2005’.

IMS, ‘Global Pharmaceutical Perspectives 2004’.


Kahrilas et al (2000), ‘Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial’, Alimentary Pharmacology and Therapeutics, 14.


Kilian and Taylor (2003), ‘Why is it so difficult to beat the random walk forecast of exchange rates?’, Journal of International Economics, 60.

King’s Fund (2006), ‘Local variations in NHS spending priorities’.


KPMG’s Corporate Tax Rate Survey (2005).


Ley 25/1990, of 20 December (1990), Titulo VIII, Article 100(2), ‘El Ministerio de Sanidad y Consumo,…, establecerá el precio industrial máximo con carácter nacional, para cada especialidad farmacéutica …’.

Ley 29/2006 of 26 July (2006), Article 87 ‘Garantías de trazabilidad’;


Medicines (Advertising) Regulations 1994, Regulation 21(l) and (3) and Regulation 23(1) and (2)


Merck, Sharp & Dohme BV v Belgium, ECJ C-245/03


Napp Pharmaceutical Holdings Limited and Subsidiaries. Decision of the Director General of Fair Trading No CA98/2/2001, 30 March 2001,


National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004, SI 2004/629, which applies only to England

National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004, SI 2004/1022, which applies only to Wales

National Health Service (Pharmaceutical Services) (Scotland) Regulations 1995, Regulation 9 (made under S.27 of NHS (Scotland) Act 1978


National Health Service (Pharmaceutical Services) Regulations 2005, Regulation 56 (1) 2005/641 and Paragraph 3 of Schedule II.

National Health Service (Scotland) Act 1978

National Health Service (Wales) Act 2006

National Health Service Act 1977, S. 2; S.11; S.16(2); S.124(4); S.126(4); S.11; S.42, Schedule 6.

National Health Service Act 2006, S.28; Ss 260 – 268; Ss 271 (3) and 278(3)

National Health Service Health Department Letter (NHS HDL) (2003) 60 of 25 November

National Health Service Health Department Letter (NHS HDL) (2006) 29 of 12 May

National Institute for Clinical Excellence (Establishment and Constitution) Order 1999, Article 3


NICE, *Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease*, NICE Health Technology Appraisal TA091.


NICE’s TA77 *Insomnia – Newer Hypnotic Drugs*


Northern Ireland Act 1998


OECD Health Data 2005.


Ofcom (2005), *Ofcom’s Approach to Risk in the Assessment of the Cost of Capital, January*.


Office of Fair Trading study, (2004) *Assessing the impact of public sector procurement on competition*


Ofwat (2005), *Regulatory Accounting Guideline v.5.04*, March.


Pharmaceutical Pricing Regulation Scheme 2005

Pharmaceutical Services Regulations (Northern Ireland) 1997, Regulation 9, SR 1997/381


PreussenElektra AG v. Schleswag AG C-379/98


R v The Secretary of State for Health ex parte Association of Pharmaceutical Importers, Association of the British Pharmaceutical Industry [2001] EWHC Admin 183


Roussel Laboratoria BV v État Néerlandais (Case 181/83, [1983] ECR 3849)

Schedule of Pharmaceutical Benefits, August 2006, 74.


Scotland Act 1998, Ss 29, 30, and J4 of Part II to Schedule 5.

Scrip magazine (2006), 'Parallel traders get smarter in declining market', May.

Sheldon TA, Cullum N, Dawson D, et al. ‘What’s the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients’ notes and interviews’, BMJ, 2004; 329:999-1006.


Stichting Farmaceutische Kengetallen, Ministerie van Volksgezondheid, Welzijn an Sport, (study comissioned by the Dutch Ministry of Health, Wellbeing and Sport), www.sfk.nl

Sudlow and Counsell (2003), ‘Problems with the UK government’s risk sharing scheme for assessing drugs for multiple sclerosis’, BMJ.

Syfait and others v. Glaxosmithkline AEVE, ECJ Case C-53/03

Synetairismos Farmakopoion Aitolias & Akarnanias (Syfait) and Others v Glaxosmithkline AEVE, Advocate General’s Opinion in Case C-53/03.

Tepea v Commission, Case C-28/77


Tischendorf, A (AT Kearney) and Nusser, M (2005), ‘The Research Based Pharmaceutical Industry as a Chance for the Business Location Germany’.


UK (R (on the application of Pfizer Ltd.)) v. Secretary of State for Health [2003] 1CMLR 19


United Brands C-27/76


West, P. and Mahon, J (2003), ‘Benefits to Payers and Patients from Parallel Trade’.


http://www.keele.ac.uk/depts/mm/MTRAC/

http://www.kpmg.com.om

http://www.lmi.no/Prisrapport%202006_h9tQk.pdf.file.


http://www.nice.org.uk (NICE technology appraisal process)

http://www.nice.org.uk/page.aspx?o = 202425

http://www.nihr.ac.uk/infrastructure_technology_platforms.aspx


http://www.opsi.gov.uk/legislation/

http://www.parliament.uk


http://www.ppa.org.uk/ppa/edt_intro.htm

http://www.previade.fr/ebn.ebn?pid=23&domain=site&site=6&uid=documentsite_5236&rub=538

http://www.psnc.org.uk

http://www.rheumatology.org.uk/public_affairs/armabsrtnfsurvey/

http://www.wales.gov.uk/keypubmrs/content/06-028.pdf

http://www.who.cc.no